Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00057616 | Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma. | PHASE3 | COMPLETED | 274 | — | — | Oct 1, 2002 | Jul 15, 2005 | Nov 8, 2019 | 49 | Australia, Estonia +7 |
| NCT00055562 | Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma | PHASE2 | COMPLETED | 274 | — | — | Jan 1, 2003 | Dec 1, 2004 | Jun 24, 2005 | 31 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| CC-5013 | DRUG | - |
| CC 5013 | DRUG | - |
* Understand and voluntarily sign an informed consent form * Able to adhere to the study visit schedule and other protocol requirements * Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy * Women of childbearing potential must have a negative serum or ...